Novartis imports some 120 million packs of medicines into the UK each year.
Keystone
Swiss pharmaceuticals giant Novartis says a no-deal Brexit could hurt patients and that it is stockpiling medicines in the UK to help ensure continuity of supply.
This content was published on
1 minute
swissinfo.ch/jc
In a press release on Friday, it said that after the British parliament’s rejection of Prime Minister Theresa May’s Brexit deal, “the risk of UK exiting the EU without a deal is increased and this will be hugely impactful for patients, particularly around the supply and safety of medicines”.
And it called for the British government to take action on medicines.
“It is vital that Government makes minimising disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly Brexit and ensures cooperation over medicines regulation in this event.”
The pharma giant said it is prioritising measures to ensure that patients in the UK can access medicines produced by Novartis and its Sandoz and Alcon affiliates. It imports some 120 million packs of medicines to the UK from Europe each year, according to the press release.
Novartis also urged the National Health Service and pharmacists in the UK to heed advice not to stockpile medicines, “so supply can be managed centrally, minimising the risk of medicine shortages across the UK”.
Novartis, maker of neurological, immunology and cancer drugs, employs around 1,500 people in the UK.
More
More
Brexit worries to keep Theresa May away from Davos
This content was published on
UK Prime Minister Theresa May, citing domestic concerns, has followed her French and American counterparts by pulling out of this year’s WEF.
This content was published on
The latest figures from the Federal Office of Public Health show that lab-confirmed cases dropped from nearly 2,340 to under 2,000 last week.
Swiss cities targeted by Russian hackers during WEF
This content was published on
Russian hackers have targeted canton Schaffhausen and the cities of Geneva and Sierre, paralysing their websites on Wednesday morning.
This content was published on
Paul Hottinguer, a member of one of Switzerland’s most famous banking families, will face trial in Paris for tax fraud and money laundering.
Swiss man who died in Iranian prison had photographed military site
This content was published on
The Iranian judiciary said that the Swiss man who died in an Iranian prison on January 9 had been detained for photographing a restricted military site.
Swiss researchers patent new device for avalanche detection
This content was published on
The WSL Institute for Snow and Avalanche Research said it has granted a group of Swiss researchers a patent for a device to enhance avalanche warnings.
Berset discusses ECHR climate ruling implementation at Davos
This content was published on
Switzerland has submitted a report on the court's ruling in Strasbourg. Berset told Justice Minister Beat Jans that the Council of Europe is reviewing it.
This content was published on
A 27-year-old ski tourer has died in the hospital in Sion, in southwestern Switzerland, after being caught in an avalanche on Saturday.
Swiss health minister criticises Trump’s ‘rash’ WHO exit
This content was published on
Switzerland has expressed “deep” regret over Trump’s decision to withdraw from the WHO, Swiss Health Minister Elisabeth Baume-Schneider said in Davos.
This content was published on
Job vacancies in Switzerland fell by 10% in 2024, marking the first negative annual balance since the Covid-19 pandemic, says Adecco.
Swiss president meets Zelensky in Davos amid tensions with Europe
This content was published on
Swiss President met Zelensky at Davos. As Zelensky thanked Switzerland, Keller-Sutter said it's too early to discuss a new summit, awaiting Trump's actions.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
This content was published on
Swiss drugmaker Novartis is exploring working with the global reinsurance industry to help bear the cost of new personalised therapies.
Too few pharma companies prioritise access to medicines
This content was published on
Novartis and Roche both get a boost in the 2018 ranking of progress in expanding access to medicines by the biggest pharmaceutical companies.
This content was published on
Sandoz Inc. and Pear Therapeutics announced that that an app to help treat opium addicts was approved in the United States.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.